April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Development of allele specific gene silencing siRNAs for TGFBI Arg124Cys in Lattice Corneal Dystrophy Type I
Author Affiliations & Notes
  • David G Courtney
    School of Biomedical Sciences, University of Ulster, Coleraine, United Kingdom
  • Sarah D Atkinson
    School of Biomedical Sciences, University of Ulster, Coleraine, United Kingdom
    Dermatology and Genetic Medicine, University of Dundee, Dundee, United Kingdom
  • Johnny E Moore
    School of Biomedical Sciences, University of Ulster, Coleraine, United Kingdom
  • Eleonora Maurizi
    School of Biomedical Sciences, University of Ulster, Coleraine, United Kingdom
    Centre for Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
  • Graziella Pellegrini
    Centre for Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
  • Graeme C Black
    Manchester Centre for Genomic Medicine, University of Manchester, Manchester, United Kingdom
    St. Mary’s Hospital, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
  • Forbes D Manson
    Manchester Centre for Genomic Medicine, University of Manchester, Manchester, United Kingdom
    St. Mary’s Hospital, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
  • Gary Hin-Fai Yam
    Tissue Engineering and Stem Cell Group, Singapore Eye Research Institute, Singapore, Singapore
  • Irwin W McLean
    Dermatology and Genetic Medicine, University of Dundee, Dundee, United Kingdom
  • Tara C B Moore
    School of Biomedical Sciences, University of Ulster, Coleraine, United Kingdom
    Dermatology and Genetic Medicine, University of Dundee, Dundee, United Kingdom
  • Footnotes
    Commercial Relationships David Courtney, None; Sarah Atkinson, None; Johnny Moore, None; Eleonora Maurizi, None; Graziella Pellegrini, None; Graeme Black, None; Forbes Manson, None; Gary Hin-Fai Yam, None; Irwin McLean, None; Tara Moore, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4069. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David G Courtney, Sarah D Atkinson, Johnny E Moore, Eleonora Maurizi, Graziella Pellegrini, Graeme C Black, Forbes D Manson, Gary Hin-Fai Yam, Irwin W McLean, Tara C B Moore; Development of allele specific gene silencing siRNAs for TGFBI Arg124Cys in Lattice Corneal Dystrophy Type I. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4069.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: This study aimed to investigate the potency and specificity of short-interfering RNA (siRNA) treatment for TGFBI-Arg124Cys lattice corneal dystrophy type I (LCDI) using both exogenous expression constructs in model systems and endogenous gene targeting in an ex vivo model using corneal epithelial cell cultures.

Methods: A panel of 19 TGFBI-Arg124Cys specific siRNAs were assessed by a dual-luciferase reporter assay. Further assessment using pyrosequencing and qRT-PCR was used to identify the lead siRNA by assessing both potency and specificity, while suppression of mutant TGFBIp was evaluated by western blot and Congo red aggregation assays. An ex vivo model of LCDI using corneal epithelial cell cultures was established using limbal biopsies from corneal dystrophy patients harbouring the Arg124Cys mutation. Treatment efficiency of the siRNA was assessed for the inhibition of the mutant allele in these corneal epithelial cells using pyrosequencing, qRT-PCR and a TGFBI ELISA.

Results: A lead siRNA was identified using exogenous constructs in a dual luciferase reporter assay, and by pyrosequencing and qRT-PCR. The potency and allele specificity of the siRNA was confirmed at the protein level in a western blot and a Congo red aggregation assay. This potency then translated to a 44% reduction of the endogenous Arg124Cys allele in the ex vivo model of LCDI, while still demonstrating allele specificity.

Conclusions: We have identified a lead siRNA specific to the TGFBI-Arg124Cys mutant allele associated with LCDI. Silencing of exogenous TGFBI was observed at both mRNA and protein levels and in an ex vivo model of LCDI with an efficient suppression of the endogenous mutant allele. This result indicates the potential of siRNA treatment as a personalized medicine approach for the management of heritable TGFBI-associated corneal dystrophies.

Keywords: 538 gene transfer/gene therapy • 482 cornea: epithelium • 519 extracellular matrix  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×